Citadel Advisors
GNOM icon

Citadel Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Citadel Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50
Closed -$2.28K – 14696
2024
Q1 		$2.28K Buy
+50
New +$2.28K ﹤0.01% 14020
2023
Q1 		– Sell
-250
Closed -$12.7K – 15000
2022
Q4 		$12.7K Buy
+250
New +$12.9K ﹤0.01% 13494

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Citadel Advisors's GNOM Position: Q2 2026 in Review

Citadel Advisors reduced its Global X Genomics & Biotechnology ETF (GNOM) stake by 0.03% in Q2 2026, selling an estimated $95 and leaving 6,179 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #10752.

Citadel Advisors first reported a position in GNOM in Q2 2020 and has held it in 11 quarters since. The position peaked at $580K in Q3 2021. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

  • Citadel Advisors held 6,179 shares of Global X Genomics & Biotechnology ETF worth $351K as of Q2 2026.
  • Citadel Advisors sold 2 Global X Genomics & Biotechnology ETF shares in Q2 2026, an estimated $95.
  • Global X Genomics & Biotechnology ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10752 holding.
  • Citadel Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q2 2020 and has held it in 11 quarters since.
  • Citadel Advisors's Global X Genomics & Biotechnology ETF position peaked at $580K in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.